Replies to post #207178 on Biotech Values

[DewDiligence]

DXCM +26% on new CMS classification for G5 continuous glucose monitor:

http://finance.yahoo.com/news/centers-medicare-medicaid-services-cms-023000591.html

It's notable that the FDA label expansion for the G5 monitor three weeks ago did nothing for the stock price (#msg-127319780), but the new CMS classification—which is what drives reimbursement—caused a big move.